Elfabrio 欧盟 - 斯洛文尼亚文 - EMA (European Medicines Agency)

elfabrio

chiesi farmaceutici s.p.a - pegunigalsidase alfa - fabryjeva bolezen - drugi zdravljene bolezni prebavil in presnove izdelki, - elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of fabry disease (deficiency of alpha-galactosidase).